From CK-MB to MicroRNAs: Evolving Biomarker Strategies for Early Diagnosis of Myocardial Infarction
International Journal of Contemporary Pathology · 2025
DOI: 10.37506/p17pqv72 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Contemporary Pathology, 2025. Verfasst von Vijjapu Devi Deepak und 9 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Myocardial infarction (MI) remains a major cause of morbidity and mortality worldwide, and accurate early diagnosis iscritical to improving clinical outcomes. High-sensitivity cardiac troponins (hs-cTn) are the current gold standard biomarkersdue to their excellent sensitivity, yet they have limitations including delayed elevation in very early infarction and reducedspecificity in patients with renal dysfunction or non-ischemic myocardial injury. This systematic review evaluated thediagnostic performance of traditional biomarkers (CK, CK-MB, myoglobin, hs-cTn) and emerging molecular approachesincluding circulating microRNAs (miRNAs) and multi-marker strategies. Seven studies and one meta-analysis wereincluded, encompassing over 23,000 patients. Classical biomarkers such as CK and CK-MB demonstrated limited sensitivitybut retained niche value in peri-procedural MI due to higher specificity, with CK-MB achieving up to 96% specificity.High-sensitivity troponins provided superior early detection with sensitivities approaching 90% but showed reducedpositive predictive value in unselected emergency department populations. Circulating miRNAs, particularly miR-499 andmiR-133a, achieved pooled sensitivities and specificities around 0.88, highlighting their potential for ultra-early MI detection.Furthermore, computational models like the ARTEMIS algorithm integrating hs-cTn with clinical variables achieved AUCsof 0.92–0.98, surpassing traditional threshold-based diagnostics and enabling personalized probability-based assessment.Overall, the findings suggest that while hs-cTn remains the primary diagnostic biomarker, combining it with molecularmarkers and advanced computational models can improve early diagnosis, specificity, and clinical decision-making inmyocardial infarction.
Zitieren
APA
Deepak, V. D., Kombathula, S. R., Asokan, A., Naiyer, G., Sharon, P., Dwivedi, K., oʻgʻli, B. J. A., Sharipov, A., Bose, S., & Shamsiddinovich, S. S. (2025). From CK-MB to MicroRNAs: Evolving Biomarker Strategies for Early Diagnosis of Myocardial Infarction. International Journal of Contemporary Pathology. https://doi.org/10.37506/p17pqv72
Vancouver
Deepak VD, Kombathula SR, Asokan A, Naiyer G, Sharon P, Dwivedi K, et al. From CK-MB to MicroRNAs: Evolving Biomarker Strategies for Early Diagnosis of Myocardial Infarction. International Journal of Contemporary Pathology. 2025. doi:10.37506/p17pqv72
BibTeX
@article{Deepak2025,
author = {Deepak, Vijjapu Devi and Kombathula, Sharon Rose and Asokan, Athulya and Naiyer, Ghina and Sharon, Patricia and Dwivedi, Kalash and oʻgʻli, Boykhurozov Jasurbek Asilbek and Sharipov, Akramkhon and Bose, Surajit and Shamsiddinovich, Srojidinov Sardor},
title = {From CK-MB to MicroRNAs: Evolving Biomarker Strategies for Early Diagnosis of Myocardial Infarction},
journal = {International Journal of Contemporary Pathology},
year = {2025},
doi = {10.37506/p17pqv72}
}
EUVIMED